Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen counts on Kairos Expertise in Biobank- Management

Published: Friday, March 30, 2012
Last Updated: Friday, March 30, 2012
Bookmark and Share
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.

"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas”, explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. „The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management.”

Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protagen, Inova Announce Agreement for BICD2 Biomarker
The license agreement will allow Inova to add the novel biomarker to their portfolio of CTD reagents to help improve diagnosis of this debilitating disease.
Friday, August 12, 2016
Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test
BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).
Thursday, June 16, 2016
Using Biomarkers to Identify Inflammation in Prostate Cancer Patients
Discovery of new biomarkers for chronic inflammation could allow the development of new, more accurate prostate cancer diagnostics.
Wednesday, March 30, 2016
Novel Route to Serum Based Prostate Cancer Diagnostics
Protagen AG has announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.
Thursday, February 11, 2016
Protagen AG Joins RA-MAP Consortium
Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has announced that it will join the RA-MAP Consortium.
Thursday, January 21, 2016
Protagen, Mikrogen Collaborate
Protagen and Mikrogen have agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.
Friday, November 13, 2015
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development
The cooperation is aimed to identify and validate biomarkers for medically relevant diseases.
Monday, October 25, 2010
Key Patent of Protagen Granted in Japan
The patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology.
Friday, August 13, 2010
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!